NCT06172348View on ClinicalTrials.gov

A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

March 28, 2024

Study Completion Date

March 28, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

Ritlecitinib

Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT06172348 - A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults | Biotech Hunter | Biotech Hunter